PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

Sara Gandini(European Institute of Oncology), Mario Mandalà(University of Perugia), Daniela Massi(University of Florence)

Critical Reviews in Oncology/Hematology

February 10, 2016

10.1016/j.critrevonc.2016.02.001

Cited by 387

Related Papers

Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma

|New England Journal of Medicine|2014|2k

Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma

|New England Journal of Medicine|2017|1.5k

Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer

|Nature Medicine|2019|1.4k

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2018|1.3k

Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation

|Nature Medicine|2019|1.1k